Identification of potential vinorelbine-associated prognostic genes in breast cancer through integrative bioinformatics and experimental validation - Report - MDSpire
Advertisement
Identification of potential vinorelbine-associated prognostic genes in breast cancer through integrative bioinformatics and experimental validation
Clinical Report: Prognostic Genes Associated with Vinorelbine in Breast Cancer
Overview
This study identifies TUBA1C, BRCA1, TGFB1, TUBA1B, XRCC1, PTGS2, IL7, and TUBB2B as prognostic genes linked to vinorelbine treatment in breast cancer.
Background
Breast cancer remains a leading cause of cancer-related mortality among women, with significant challenges in treatment due to its heterogeneity. Identifying robust prognostic indicators specific to breast cancer is crucial.
Data Highlights
No numerical data available.
Key Findings
Eight prognostic genes were identified: TUBA1C, BRCA1, TGFB1, TUBA1B, XRCC1, PTGS2, IL7, and TUBB2B.
The random survival forest model and nomogram were constructed.
Immune microenvironment analysis indicated correlations between risk scores and immune cell presence.
Macrophages were identified as key players in breast cancer development.
RT-qPCR revealed differential expression of prognostic genes in breast cancer samples compared to vinorelbine-treated samples.
Clinical Implications
The identified prognostic genes may assist in tailoring vinorelbine-based therapies for breast cancer patients. Understanding the immune microenvironment's role could enhance treatment strategies and patient outcomes.
Conclusion
The findings identify prognostic markers associated with vinorelbine treatment in breast cancer.
